Pinhal Novo, Portugal

Margarida Figueiredo

This inventor holds 1 USPTO granted patent and 1 EPO patent. Top assignee: Hovione Scientia Limited. Active years: 2020.


 

Average Co-Inventor Count = 5.0

ph-index = 1

Forward Citations = 5(Granted Patents)


Company Filing History:


Years Active: 2020

Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: Innovations by Margarida Figueiredo

Introduction

Margarida Figueiredo is a notable inventor based in Pinhal Novo, Portugal. She has made significant contributions to the field of pharmaceuticals, particularly in the development of tetracycline salts. Her work has implications for the treatment and prevention of inflammation and infections.

Latest Patents

Margarida Figueiredo holds a patent for "Salts of tetracyclines." This invention involves a tetracycline salt that comprises a tetracycline and an organic acid, specifically oxalic acid or maleic acid. The preferred tetracyclines include doxycycline, minocycline, sancycline, lymecycline, tetracycline, and demeclocycline. The patent also details preferred salts such as oxycycline maleate, minocycline oxalate, and others. Additionally, it provides a pharmaceutical formulation that includes these tetracycline salts for use as medicaments.

Career Highlights

Margarida Figueiredo is associated with Hovione Scientia Limited, where she continues to innovate in the pharmaceutical sector. Her work focuses on enhancing the efficacy of tetracycline-based treatments.

Collaborations

Margarida has collaborated with notable colleagues, including Luis Sobral and Livia Santana De Arruda. These collaborations have contributed to her research and development efforts in the pharmaceutical field.

Conclusion

Margarida Figueiredo's contributions to the field of pharmaceuticals through her innovative patents highlight her role as a significant inventor. Her work continues to impact the treatment of infections and inflammation, showcasing the importance of innovation in medicine.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…